Breaking News Bar

Business News and Information

The Daily Herald Market Index
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Local Stocks
TEVAPHARMIND SP ADR (NY: TEVA)
22.18 USD  +0.55 (+2.54%)
Official Closing Price  /  Updated: 8:04 PM EDT, May 25, 2018  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 13,239,575
Open 21.57
Bid (Size) 22.25 (100)
Ask (Size) 22.33 (100)
Prev. Close 21.63
Today's Range 21.55 - 22.18
52wk Range 10.85 - 33.82
Shares Outstanding 1,016,290,682
Dividend Yield 5.37%
Performance
YTD
+16.06%
+16.06%
1 Month
+28.43%
+28.43%
3 Month
+10.68%
+10.68%
6 Month
+61.90%
+61.90%
1 Year
-22.74%
-22.74%
Top News
More News
Research Report Identifies Brady, RA PHARMCTL INC, Sigma Designs, Teva Pharmaceutical Industries, Bridge, and BOK Financial with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Brady Corporation... Read More
from GlobeNewswire News Releases
Teva Confirms September PDUFA Date for Fremanezumab
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today confirmed that the U.S. Food and Drug Administration (FDA) has extended the goal date of the Biologics License Application (BLA) for... Read More
from Business Wire News Releases
More News
Read More
CORRECTING and REPLACING Teva Announces Publication of Phase III Trial Data of Fremanezumab for the Preventive Treatment of Episodic Migraine in the Journal of the American Medical Association
from Business Wire News Releases
Teva Pharmaceutical Earns IBD Rating Upgrade
from Investor's Business Daily
Amgen Wins Race To Migraine Prevention Drug — Lilly, Teva, Alder Trail
from Investor's Business Daily
UPDATE 2-India's Sun Pharma warns U.S. pricing pressure to hit 2019 profit
category companyNews
from Reuters: Company News
Jim Cramer Gives His Opinion On Blue Apron, Teva And More
category INCY , Jim Cramer , ETFC , and 11 more.
from Benzinga
Cramer's lightning round: I don't have a thesis for Blue Apron, so don't buy
category Personal investing , Investing , Incyte Corporation , and 12 more.
from CNBC.com News
UPDATE 1-Teva hopes to launch migraine drug as soon as September
category companyNews
from Reuters: Company News
Is This Little Biotech the Best Migraine Stock to Buy Now?
category TEVA , AMGN , Market News , and 3 more.
from Motley Fool
Teva Pharm says FDA to decide on migraine drug on Sept 16
category companyNews
from Reuters: Company News
Stock Market JSON API provided by www.cloudquote.net
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
 
bottom clear
Search DailyHerald.com for articles
More ways to search Daily Herald
Obituaries
Search DailyHerald.com obituaries. » Daily Herald newspaper archive
Find archived newspaper articles back to 1901. »
Digital Subscriptions
Activate Subscriber Access Purchase a Digital Subscription
Home Delivery
Start a New Subscription Manage Account